Follow-The-Filings

Security · featured owners

ACRS Aclaris Therapeutics Inc.

Health Care COM Equity as of 2026 Q2 among managers we track

  • 1 Owner
  • Max 1.2%
  • $9M

ACRS (Aclaris Therapeutics Inc.) is held in 1 featured 13F book as of 2026 Q2. Palo Alto Investors is the largest tracked holder by portfolio weight (1.2%). Figures are as-filed 13F, not free float.

Who owns this now

Largest portfolio weights among featured holders · max 1.2% (Palo Alto Investors) · not free-float ownership

  1. Palo Alto Investors 1.2%

holders

sorted by value · long equity only · current book 2026 Q2 · open a manager for their book

history
Palo Alto Investors 2026 Q2 1.2% Hold 1,613,430 $9M history

1 current · options excluded

SEC filings

Recent issuer filings from EDGAR · 14 shown · open Filing / Doc on SEC.gov

Filed Form Detail Links
8-K 2.02,9.01 Filing Doc
10-Q Filing Doc
8-K 1.01,9.01 Filing Doc
8-K 5.07 Filing Doc
8-K 2.02,9.01 Filing Doc
10-Q Filing Doc
8-K 7.01,8.01,9.01 Filing Doc
DEFA14A Filing Doc
8-K 7.01 Filing Doc
8-K 7.01 Filing Doc
8-K 2.02,9.01 Filing Doc
10-K Filing Doc
8-K 7.01,9.01 Filing Doc
8-K 7.01,8.01,9.01 Filing Doc

Insider forms

Form 3 / 4 / 5 from EDGAR · 11 rows shown

Filed Form Detail Links
4 Period Aug 1, 2026 Filing Doc
4 Period Jun 4, 2026 · 6 forms Filing Doc
4 Period May 1, 2026 Filing Doc
4 Period Apr 27, 2026 Filing Doc
4 Period Mar 1, 2026 Filing Doc
4 Period Feb 2, 2026 · 6 forms Filing Doc
4/A Period Feb 1, 2026 Filing Doc
4 Period Feb 3, 2026 · 4 forms Filing Doc
4/A Period Feb 1, 2025 Filing Doc
4 Period Feb 1, 2026 · 2 forms Filing Doc
4 Period Dec 31, 2025 Filing Doc

Updated 5 days ago Source: SEC EDGAR submissions All on EDGAR

financials

US-GAAP annual · as tagged in Form 10-K · fiscal years · values link to the SEC filing

Income statement

Metric FY2023 FY2024 FY2025
Revenue $31.25M $18.72M $7.83M
Gross profit * $27.83M $15.93M $5.74M
Gross margin * 89.0% 85.1% 73.3%
Net income -$88.48M -$132.06M -$64.92M
Net margin * -283.1% -705.5% -829.6%

Balance sheet

Metric FY2023 FY2024 FY2025
Total current assets $128.86M $125.95M $96.32M
Total non-current assets * $68.55M $94.38M $64.14M
Total assets $197.4M $220.33M $160.46M
Total current liabilities $30.95M $31.6M $28.64M
Total non-current liabilities * $9.27M $33.18M $28.73M
Total equity $157.18M $155.55M $103.08M

Cash flow

Metric FY2023 FY2024 FY2025
Cash from operations -$78.32M -$20.08M -$47.11M
Cash from investing $46.22M -$69.77M $48.36M
Cash from financing $26.71M $74.54M -$5.86M
Net change in cash -$5.4M -$15.31M -$4.61M

Source: SEC companyfacts (US-GAAP 10-K) · * = computed (not a single XBRL tag) · fiscal year as labeled by the issuer · not adjusted or audited by Follow-The-Filings

ownership over time

filing count by report period · click a bar for that quarter’s holders